Understanding how certain genes that promote cell death are regulated in cancer cells

The Translational Regulation of Pro-apoptotic Genes

NIH-funded research Ohio State University · NIH-10854937

This study is looking at how a protein called pRB helps control genes that can cause cancer cells to die, and it’s for anyone interested in new ways to make cancer treatments more effective by understanding what happens when pRB is missing.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionOhio State University NIH-funded
Lab location1 site (Columbus, UNITED STATES)
Project IDNIH-10854937 on NIH RePORTER

What this research studies

This research investigates the mechanisms by which the Retinoblastoma 1 protein (pRB) influences the expression of genes that can lead to cell death in cancer. It focuses on how the loss of pRB affects the translation of pro-apoptotic genes, which are crucial for preventing uncontrolled cell growth. By profiling RNA and protein changes in cancer cells lacking pRB, the study aims to identify RNA-binding proteins that inhibit the translation of these important genes. The findings could reveal new targets for cancer therapies that enhance cell death in tumors.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers characterized by the inactivation of the Retinoblastoma 1 protein.

Not a fit: Patients whose cancers do not involve pRB inactivation may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that effectively induce cell death in cancer cells, potentially improving outcomes for patients with certain types of cancer.

How similar studies have performed: Previous research has shown promising results in targeting apoptotic pathways in cancer, suggesting that this approach could be effective.

Where this research is happening

Columbus, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancer Cell GrowthCancer ModelCancer TreatmentCancerModel
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.